Photobiomodulation and conditioned medium of adipose-derived stem cells for enhancing wound healing in rats with diabetes: an investigation on the proliferation phase.
Pourhashemi E., Amini A., Ahmadi H., Ahrabi B., Mostafavinia A., Omidi H.
Prospective Study on Type 1 Diabetes, Chronic Wound, published in Lasers Med Sci (2024) — summary generated from the PubMed abstract.
Early human evidence such as case series or small samples is exploring possible benefits.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Prospective Study
- Journal
- Lasers Med Sci (2024)
- Country
- England
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 38270723
- DOI
- 10.1007/s10103-024-03974-8
- Citations
- 6
Abstract (original English)
This investigation tried to evaluate the combined and solo effects of photobiomodulation (PBM) and conditioned medium derived from human adipose tissue-derived stem cells (h-ASC-CM) on the inflammatory and proliferative phases of an ischemic infected delayed healing wound model (IIDHWM) in rats with type I diabetes mellitus (TIDM). The present investigation consisted of four groups: group 1 served as the control, group 2 treated with h-ASC-CM, group 3 underwent PBM treatment, and group 4 received a combination of h-ASC-CM and PBM. Clinical and laboratory assessments were conducted on days 4 and 8. All treatment groups exhibited significantly higher wound strength than the group 1 (p = 0.000). Groups 4 and 3 demonstrated significantly greater wound strength than group 2 (p = 0.000). Additionally, all therapeutic groups showed reduced methicillin -resistant Staphylococcus aureus (MRSA) in comparison with group 1 (p = 0.000). While inflammatory reactions, including neutrophil and macrophage counts, were significantly lower in all therapeutic groups rather than group 1 on days 4 and 8 (p < 0.01), groups 4 and 3 exhibited superior results compared to group 2 (p < 0.01). Furthermore, proliferative activities, including fibroblast and new vessel counts, as well as the measurement of new epidermal and dermal layers, were significantly increased in all treatment groups on 4 and 8 days a
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
Evidence level
Early human evidence such as case series or small samples is exploring possible benefits.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.
Related research
- Level AMeta-analysisEurope PMC
Transforming hypoglycemia prediction in adult type 1 diabetes: a systematic review and meta-analysis for precision care
Meta-analysis on Type 1 Diabetes, published in Open Life Sci (2026) — summary generated from the PubMed abstract.
- 2026
Open Life Sci - Level ASystematic ReviewEurope PMC
Long-term storage, cryopreservation, and culture of isolated human islets: a systematic review
Systematic Review on Type 1 Diabetes, published in Front Transplant (2025) — summary generated from the PubMed abstract.
- 2025
Front Transplant - Level AMeta-analysisEurope PMC
Change in Viability and Function of Pancreatic Islets after Coculture with Mesenchymal Stromal Cells: A Systemic Review and Meta-Analysis
Meta-analysis on Type 1 Diabetes, published in J Diabetes Res (2020) — summary generated from the PubMed abstract.
- 2020
J Diabetes Res7 citations - Level AMeta-analysisEurope PMC
Stem cell therapy for patients with diabetes: a systematic review and meta-analysis of metabolomics-based risks and benefits
Meta-analysis on Type 1 Diabetes, Type 2 Diabetes, published in Stem Cell Investig (2018) — summary generated from the PubMed abstract.
- 2018
Stem Cell Investig22 citations - Level AMeta-analysisEurope PMC
Clinical Efficacy of Stem Cell Therapy for Diabetes Mellitus: A Meta-Analysis
Meta-analysis with a reported sample of 524 on Type 1 Diabetes, published in PLoS One (2016) — summary generated from the PubMed abstract.
- 2016
- n = 524
PLoS One81 citations - Level BClinical TrialEurope PMC
Stem Cell-Derived Beta-Cell Therapies: Encapsulation Advances and Immunological Hurdles in Diabetes Treatment
Clinical Trial on Type 1 Diabetes, Type 2 Diabetes, Scar, published in Cells (2026) — summary generated from the PubMed abstract.
- 2026
Cells1 citations